SLA-p35: A Promising Drug Target and Biomarker for the Treatment of SEPSECS

Target Name: SEPSECS

NCBI ID: G51091

SEPSECS

SLA-p35: A Promising Drug Target and Biomarker for the Treatment of SEPSECS

Sepsis is a life-threatening condition that affects millions of people worldwide, leading to severe tissue damage, inflammation, and even death. The immune response to an invading pathogen can result in the formation of a body's immune response, which is typically characterized by an exaggerated and dysregulated response. SEPSECS, or systemic-inflammatory response to an infection-related challenge, is a type of sepsis that occurs in individuals with underlying cardiovascular diseases, such as heart failure, hypertension, and diabetes. SEPSECS is a serious and life-threatening condition that requires effective treatment to prevent tissue damage and mortality.

SLA-p35: A Potential Drug Target and Biomarker

SLA-p35 (serine/thiobutylamine-conjugated p35) is a protein that is expressed in various tissues and cells, including the lungs, heart, kidneys, liver, and pancreas. SLA-p35 is involved in the regulation of cellular processes, including inflammation, stress responses, and cell death. SLA-p35 has been shown to play a key role in the development and progression of SEPSECS.

Recent studies have suggested that SLA-p35 may be a potential drug target for the treatment of SEPSECS. By inhibiting the activity of SLA-p35, researchers may be able to reduce the severity and duration of SEPSECS. Additionally, SLA-p35 has been shown to be involved in the development of cardiomyopathy, a common complication in people with SEPSECS. By targeting SLA-p35, researchers may be able to develop new treatments for SEPSECS that specifically target this protein and prevent cardiomyopathy.

SLA-p35 is also a potential biomarker for the diagnosis and monitoring of SEPSECS. The level of SLA-p35 in body fluids, such as blood or urine, can be used as a diagnostic marker for SEPSECS. Additionally, changes in SLA-p35 levels may be an indication of the severity and progression of SEPSECS. Monitoring SLA-p35 levels in SEPSECS patients may help doctors to understand the severity of the condition and to develop more effective treatments.

SLA-p35's Role in SEPSECS

SLA-p35 is involved in the regulation of various cellular processes that are critical for the development and progression of SEPSECS. One of the main functions of SLA-p35 is to regulate the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6. These cytokines are involved in the recruitment of immune cells to the site of infection, as well as the production of tissue damage and inflammation. By regulating the production of these cytokines, SLA-p35 helps to maintain the dysregulated state that is characteristic of SEPSECS.

SLA-p35 is also involved in the regulation of the production of anti-inflammatory cytokines, such as IL-10. These cytokines help to counteract the pro-inflammatory effects of SLA-p35 and help to maintain a more balanced state of inflammation in the body. By regulating the production of these cytokines, SLA-p35 helps to protect against the development and progression of SEPSECS.

In addition to its role in cytokine regulation, SLA-p35 is also involved in the regulation of cellular stress responses. SEPSECS is a stress response that occurs in response to an

Protein Name: Sep (O-phosphoserine) TRNA:Sec (selenocysteine) TRNA Synthase

Functions: Converts O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec) required for selenoprotein biosynthesis

The "SEPSECS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEPSECS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets